{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:01:45Z","timestamp":1792047705107,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106063","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:20:03Z","timestamp":1773174003000},"page":"106063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5910-3934","authenticated-orcid":false,"given":"S.","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5430-8957","authenticated-orcid":false,"given":"E.L.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kacik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Storniolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9646-1260","authenticated-orcid":false,"given":"C.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8147-335X","authenticated-orcid":false,"given":"I.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Stearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-0876","authenticated-orcid":false,"given":"R.","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-6249","authenticated-orcid":false,"given":"A.J.","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Melisko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-5895","authenticated-orcid":false,"given":"C.","family":"Wabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3817-8499","authenticated-orcid":false,"given":"J.","family":"Geradts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-5944","authenticated-orcid":false,"given":"I.","family":"Krop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kochupurakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"G.I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-4814","authenticated-orcid":false,"given":"H.S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.106063_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106063_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106063_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.106063_bib6","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2\u2212 early breast cancer: primary results from the phase III NATALEE trial","volume":"41","author":"Slamon","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106063_bib7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106063_bib8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106063_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib10","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1038\/s41467-021-23612-z","article-title":"Clinical CDK4\/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2","volume":"12","author":"Pack","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106063_bib11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/djy109","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+\/HER2\u2212 advanced breast cancer","volume":"111","author":"Di\u00e9ras","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2026.106063_bib12","series-title":"Use of Aperio Image Analysis in Peer-Reviewed Breast Cancer Research. Leica Biosystems Imaging","author":"Moroney","year":"2017"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106063_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2307\/2532300","article-title":"Relative risk trees for censored survival data","volume":"48","author":"LeBlanc","year":"1992","journal-title":"Biometrics"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.106063_bib16","volume":"40","author":"Finn","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41523-022-00399-w","article-title":"A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis","volume":"8","author":"Krishnamurthy","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106063_bib18","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/curroncol29030145","article-title":"The impact of real-world alternative dosing strategies of palbociclib on progression-free survival in patients with metastatic breast cancer","volume":"29","author":"Fu","year":"2022","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106063_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100629","article-title":"Health-related quality of life in breast cancer patients treated with CDK4\/6 inhibitors: a systematic review","volume":"7","author":"Di Lauro","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib20","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106063_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-021-06215-6","article-title":"Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2\u2212 metastatic breast cancer","volume":"188","author":"Kristensen","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106063_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","article-title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"125","author":"Burris","year":"2021","journal-title":"Br J Cancer"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106063_bib23","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1200\/JCO.2022.40.16_suppl.1017","article-title":"Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+\/HER2\u2212 advanced breast cancer (ABC) in MONALEESA(ML)-2","volume":"40","author":"Hart","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2026.106063_bib24","doi-asserted-by":"crossref","first-page":"PD17-12","DOI":"10.1158\/1538-7445.SABCS22-PD17-12","article-title":"Abstract PD17-12: primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+\/HER2\u2212 advanced breast cancer","volume":"83","author":"Cardoso","year":"2023","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.esmoop.2026.106063_bib25","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106063_bib27","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106063_bib28","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-021-04263-9","article-title":"Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+\/HER2\u2212 advanced breast cancer in Chinese women","volume":"88","author":"Xu","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106063_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314534","article-title":"Biomarkers of response and resistance to CDK4\/6 inhibitors in breast cancer: hints from liquid biopsy and microRNA exploration","volume":"23","author":"Krasniqi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106063_bib31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/diagnostics10080573","article-title":"Ki67 and PR in patients treated with CDK4\/6 inhibitors: a real-world experience","volume":"10","author":"Palleschi","year":"2020","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1078-0432.CCR-21-1628","article-title":"Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+\/HER2\u2212 breast cancer","volume":"28","author":"Dowsett","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106063_bib33","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4161\/cc.21195","article-title":"Therapeutic response to CDK4\/6 inhibition in breast cancer defined by ex vivo analyses of human tumors","volume":"11","author":"Dean","year":"2012","journal-title":"Cell Cycle"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106063_bib34","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O\u2019Leary","year":"2018","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106063_bib35","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.18632\/oncotarget.3364","article-title":"MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition","volume":"6","author":"Kovatcheva","year":"2015","journal-title":"Oncotarget"},{"issue":"37","key":"10.1016\/j.esmoop.2026.106063_bib36","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1038\/s41388-018-0332-y","article-title":"PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4\/6 inhibitor therapy-induced senescence","volume":"37","author":"Klein","year":"2018","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106063_bib37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1078-0432.CCR-23-2378","article-title":"Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma","volume":"30","author":"Gleason","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106063_bib38","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106063_bib39","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/1078-0432.CCR-20-1566","article-title":"The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer","volume":"27","author":"Jacob","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106063_bib40","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3390\/cancers15041306","article-title":"CDK4\/6 inhibitors overcome endocrine ESR1 mutation-related resistance in metastatic breast cancer patients","volume":"15","author":"Crucitta","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"25","key":"10.1016\/j.esmoop.2026.106063_bib41","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106063_bib42","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1186\/s12885-022-10078-5","article-title":"PIK3CA mutation status, progression and survival in advanced HR + \/HER2\u2212 breast cancer: a meta-analysis of published clinical trials","volume":"22","author":"Fillbrunn","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib43","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1038\/s41598-021-86238-7","article-title":"Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients","volume":"11","author":"Muendlein","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106063_bib45","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106063_bib46","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106063_bib47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106063_bib48","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106063_bib49","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","article-title":"Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion","volume":"42","author":"Kudo","year":"2024","journal-title":"Cancer Cell"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.106063_bib50","volume":"41","author":"Sonke","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106063_bib51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.breast.2023.03.015","article-title":"Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer","volume":"69","author":"Rugo","year":"2023","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-022-00479-x","article-title":"Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.106063_bib53","doi-asserted-by":"crossref","unstructured":"Llombart A, Perez-Garcia J, Bellet M, et al. PARSIFAL-LONG: extended follow-up of hormone receptor positive\/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. San Antonio, TX. Abstract RF01-03.","DOI":"10.1158\/1538-7445.SABCS23-RF01-03"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106063_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:32:17Z","timestamp":1776699137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926000050"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106063","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106063"}}